{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:07:12Z","timestamp":1791648432248,"version":"4.3.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,7]]},"abstract":"<jats:title>Lay Summary<\/jats:title>\n               <jats:p>We evaluated whether adding 5-aminosalicylic acid (5-ASA) to vedolizumab therapy helps prevent relapse in ulcerative colitis (UC) and Crohn\u2019s disease (CD). Using a large Japanese claims database, we found no benefit of 5-ASA in maintaining remission for either UC or CD. These findings suggest that combining 5-ASA with vedolizumab may not be beneficial.<\/jats:p>","DOI":"10.1093\/ibd\/izaf088","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T05:18:45Z","timestamp":1749100725000},"page":"2036-2039","source":"Crossref","is-referenced-by-count":4,"title":["Lack of Efficacy of Concomitant 5-Aminosalicylic Acid With Vedolizumab in Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3369-5059","authenticated-orcid":false,"given":"Yu","family":"Nishida","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8808-5672","authenticated-orcid":false,"given":"Shuhei","family":"Hosomi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka City University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumie","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieko","family":"Nakata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ominami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nadatani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusei","family":"Fukunaga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Otani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University , Abeno-ku, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"issue":"3","key":"2025070803374457400_CIT0001","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol."},{"issue":"1","key":"2025070803374457400_CIT0002","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis."},{"issue":"5","key":"2025070803374457400_CIT0003","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1053\/j.gastro.2020.01.007","article-title":"AGA technical review on the management of moderate to severe ulcerative colitis","volume":"158","author":"Singh","year":"2020","journal-title":"Gastroenterology."},{"issue":"1","key":"2025070803374457400_CIT0004","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis."},{"issue":"6","key":"2025070803374457400_CIT0005","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase","year":"2021","journal-title":"J Gastroenterol."},{"issue":"11","key":"2025070803374457400_CIT0006","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1016\/j.cgh.2018.11.062","article-title":"Concomitant use of aminosalicylates is not associated with improved outcomes in patients with ulcerative colitis escalated to vedolizumab","volume":"17","author":"Ma","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"6","key":"2025070803374457400_CIT0007","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut."},{"issue":"8","key":"2025070803374457400_CIT0008","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41395-018-0144-2","article-title":"No benefit of concomitant 5-aminosalicylates in patients with ulcerative colitis escalated to biologic therapy: pooled analysis of individual participant data from clinical trials","volume":"113","author":"Singh","year":"2018","journal-title":"Am J Gastroenterol."},{"issue":"6","key":"2025070803374457400_CIT0009","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1136\/gutjnl-2018-317021","article-title":"Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts","volume":"68","author":"Ungaro","year":"2019","journal-title":"Gut."},{"issue":"5","key":"2025070803374457400_CIT0010","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.cgh.2019.08.012","article-title":"Stopping mesalamine therapy in patients with Crohn\u2019s disease starting biologic therapy does not increase risk of adverse outcomes","volume":"18","author":"Ungaro","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"12","key":"2025070803374457400_CIT0011","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/ecco-jcc\/jjad113","article-title":"Impact of concomitant 5-aminosalicylic acid therapy on vedolizumab efficacy and safety in inflammatory bowel disease: post hoc analyses of clinical trial data","volume":"17","author":"Ungaro","year":"2023","journal-title":"J Crohns Colitis."},{"key":"2025070803374457400_CIT0012","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf001","article-title":"Impact of 5-aminosalicylic acid on ustekinumab in inflammatory bowel disease: a retrospective medical claims analysis","author":"Nishida","year":"2025","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2025070803374457400_CIT0013","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jgh.16786","article-title":"Evaluating the effects of 5-aminosalicylic acid on tofacitinib treatment in ulcerative colitis","volume":"40","author":"Nishida","year":"2024","journal-title":"J Gastroenterol Hepatol."},{"issue":"10","key":"2025070803374457400_CIT0014","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis."},{"issue":"1","key":"2025070803374457400_CIT0015","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2009.05.033","article-title":"5-Aminosalicylic acid inhibits TGF-beta1 signalling in colorectal cancer cells","volume":"287","author":"Koelink","year":"2010","journal-title":"Cancer Lett."},{"issue":"3","key":"2025070803374457400_CIT0016","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/s0016-5085(99)70182-4","article-title":"Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes","volume":"116","author":"Kaiser","year":"1999","journal-title":"Gastroenterology."},{"issue":"3","key":"2025070803374457400_CIT0017","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1055\/s-2000-135","article-title":"Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel","volume":"32","author":"Reinacher-Schick","year":"2000","journal-title":"Endoscopy."},{"issue":"2","key":"2025070803374457400_CIT0018","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2174\/157340611794859325","article-title":"Interaction of mesalasine (5-ASA) with translational initiation factors eIF4 partially explains 5-ASA anti-inflammatory and anti-neoplastic activities","volume":"7","author":"Lyakhovich","year":"2011","journal-title":"Med Chem."},{"issue":"1","key":"2025070803374457400_CIT0019","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.gastro.2006.10.016","article-title":"5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint","volume":"132","author":"Luciani","year":"2007","journal-title":"Gastroenterology."},{"issue":"2","key":"2025070803374457400_CIT0020","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.bcp.2012.10.026","article-title":"Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1","volume":"85","author":"Khare","year":"2013","journal-title":"Biochem Pharmacol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izaf088\/63437548\/izaf088.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/7\/2036\/63437548\/izaf088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/7\/2036\/63437548\/izaf088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T07:37:46Z","timestamp":1751960266000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/7\/2036\/8156914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,5,21]]},"published-print":{"date-parts":[[2025,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf088","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,5,21]]}}}